

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL SEARCHING AUTHORITY

To:

see form PCT/ISA/220

PCT

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1)

		Date of mailing (day/month/year) see form PCT/ISA/210 (second sheet)
Applicant's or agent's file reference see form PCT/ISA/220		<b>FOR FURTHER ACTION</b> See paragraph 2 below
International application No. PCT/IB2004/003448	International filing date (day/month/year) 21.10.2004	Priority date (day/month/year) 22.10.2003
International Patent Classification (IPC) or both national classification and IPC C07H19/06, C07H1/00		
Applicant CLARIANT LIFE SCIENCE MOLECULES (ITALIA) S.P.A.		

1. This opinion contains indications relating to the following items:

- Box No. I Basis of the opinion
- Box No. II Priority
- Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- Box No. IV Lack of unity of invention
- Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- Box No. VI Certain documents cited
- Box No. VII Certain defects in the international application
- Box No. VIII Certain observations on the international application

2. **FURTHER ACTION**

If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA:   European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016	Authorized Officer  Telephone No. +31 70 340-	
--	---	---

IAP20 Rec'd PCT/PTO 21 APR 2006

---

Box No. I Basis of the opinion

---

1. With regard to the **language**, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.  
 This opinion has been established on the basis of a translation from the original language into the following language , which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).
2. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
  - a. type of material:  
 a sequence listing  
 table(s) related to the sequence listing
  - b. format of material:  
 in written format  
 in computer readable form
  - c. time of filing/furnishing:  
 contained in the international application as filed.  
 filed together with the international application in computer readable form.  
 furnished subsequently to this Authority for the purposes of search.
3.  In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additional comments:

**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

International application No.  
PCT/IB2004/003448

---

**Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or  
industrial applicability; citations and explanations supporting such statement**

---

**1. Statement**

Novelty (N)	Yes:	Claims	2
	No:	Claims	1, 3-8
Inventive step (IS)	Yes:	Claims	2
	No:	Claims	1, 3-8
Industrial applicability (IA)	Yes:	Claims	1-8
	No:	Claims	

**2. Citations and explanations**

**see separate sheet**

10/576598

IAP20 Recd PCT/PTO 21 APR 2006

**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING  
AUTHORITY (SEPARATE SHEET)**

International application No.

PCT/IB2004/003448

**Re Item V**

**Reasoned statement with regard to novelty, inventive step or industrial applicability;  
citations and explanations supporting such statement**

Reference is made to the following document:

D1: US4340729

**Novelty**

The present application does not meet the criteria of Article 33(1) PCT, because the subject-matter of claims 1, 3-8 is not new in the sense of Article 33(2) PCT.

The document D1 discloses (column 3 lines 27-41, column 5 lines 34-60) a synthetic route towards doxifluridine which falls within claims 1, 3-8. It could be argued that the present application is novel over D1 since the addition of the Lewis acid in claim 1 is performed below 0°C whereas in D1 this is done under cooling with ice. However, the temperature of a reaction performed under cooling with ice is 0°C, however, **with a certain margin of uncertainty**. Thus, a claim stating a temperature below 0°C is still not novel over D1.

**Inventive step**

The present application does not meet the criteria of Article 33(1) PCT, because the subject-matter of claims 1, 3-8 does not involve an inventive step in the sense of Article 33(3) PCT since D1 provides the same solution to the same problem as the present application.